Yahoo Web Search

Search results

    • Small Business - Salisbury Post | Salisbury Post

      The Salisbury Post· 8 minutes ago

      TuHURA Biosciences and Kintara Therapeutics Announce Positive Results from Phase 1b Trial of IFx-2.0, a Novel Personalized Cancer Vaccine, in Checkpoint Inhibitor Resistant Advanced Merkel Cell Carcinoma (MCC) and Cutaneous Squamous Cell Carcinoma